Unicycive Therapeutics (NASDAQ:UNCY) Given “Speculative Buy” Rating at Benchmark

Benchmark reissued their speculative buy rating on shares of Unicycive Therapeutics (NASDAQ:UNCY) in a research report report published on Monday, Benzinga reports. Benchmark currently has a $3.00 price objective on the stock.

Other equities analysts have also recently issued reports about the stock. Piper Sandler assumed coverage on shares of Unicycive Therapeutics in a research note on Thursday, April 4th. They issued an overweight rating and a $9.00 target price for the company. Noble Financial assumed coverage on Unicycive Therapeutics in a report on Wednesday, February 14th. They set an outperform rating and a $6.00 price target for the company. Finally, HC Wainwright reaffirmed a buy rating and set a $4.50 price target on shares of Unicycive Therapeutics in a report on Monday, April 1st.

Unicycive Therapeutics Trading Up 3.1 %

NASDAQ:UNCY opened at $1.16 on Monday. Unicycive Therapeutics has a 1-year low of $0.47 and a 1-year high of $1.82. The firm has a fifty day simple moving average of $1.39 and a 200 day simple moving average of $0.96. The stock has a market capitalization of $40.14 million, a PE ratio of -0.75 and a beta of 2.66.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Thursday, March 28th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.02. On average, equities analysts predict that Unicycive Therapeutics will post -0.58 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Unicycive Therapeutics

Several hedge funds have recently added to or reduced their stakes in UNCY. Ground Swell Capital LLC acquired a new stake in shares of Unicycive Therapeutics during the second quarter worth $26,000. Citadel Advisors LLC acquired a new stake in shares of Unicycive Therapeutics during the fourth quarter worth $31,000. Two Sigma Advisers LP acquired a new stake in shares of Unicycive Therapeutics during the first quarter worth $31,000. State Street Corp acquired a new stake in shares of Unicycive Therapeutics during the first quarter worth $74,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Unicycive Therapeutics during the second quarter worth $123,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.